I've had this stock from the $1.25 TO $4.00 range and have lost any faith that this company can avoid bankruptcy. The clinical trials have been going on for over 2 years and have not been completed as far as anyone knows. Their balance sheets show very meager income and sales of only 1 or 2 units compared to the 30-40 units sold in the past. Their inventories are depleted and they owe significant amounts of money to their suppliers.
That all said and done, the technology and the concepts are fantastic, but it takes more than a good idea to become a success. If they don't go BK, I'd expect a huge dilution in share value due to the reissue or reverses split.
News 
Market Data 
Discover 
